CGChandradhish Ghosh

Chandradhish Ghosh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chandradhish Ghosh has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Developing antisense oligomer biotics “asobiotics” as precision antibacterials: designs, strategies, and considerations for future success

    by Dina A Moustafa, Chandradhish Ghosh, Jakob Jung, Amila Nanayakkara, Madhab Sapkota, Kanna Nagamatsu, Bruce Geller, Jörg Vogel, Joanna B Goldberg, David E Greenberg

    Antimicrobial resistance poses a pressing global health challenge in the 21st century. The rapid increase and prevalence of multidrug-resistant bacteria will require novel approaches to develop new antibiotics. Major advances in nucleic acid-based therapeutics, particularly antisense technologies, could be one solution for developing precision antibiotics. The selectivity and specificity in the drug design of antibacterial antisense oligomers (ASOs) allows precise gene-specific silencing and ultimately enables targeting of currently undruggable gene products. Our goal here is to comprehensively review the advances in asobiotics (antisense oligomer biotics) leading to therapeutic success, including modifications in the nucleic acid backbone of ASOs, which have improved their properties and progresses in delivery. We will discuss utilization of ASOs against several pathogens, strategies to overcome resistance, and finally future scenarios and prospects for asobiotics as pathogen-specific therapy in the clinic.


  • Open Access

    Design of galectin-1-conjugated nanoparticles as potential immunomodulatory agents

    by Chandradhish Ghosh, Ling Yao, Marilet Sigler, Santiago Di Lella, Alejandro J. Cagnoni, Gabriel A. Rabinovich, Peter H. Seeberger

    Galectin-1 conjugated to glucose-stabilized gold nanoparticles retains its immunomodulatory function and provides a promising platform for treating autoimmune and chronic inflammatory diseases.


  • Open Access

    An antisense oligomer conjugate with unpredicted bactericidal activity against Fusobacterium nucleatum

    by Valentina Cosi, Jakob Jung, Linda Popella, Falk Ponath, Chandradhish Ghosh, Lars Barquist, Jörg Vogel

    Fusobacteria are commensal members of the oral microbiome that can spread from their primary niche and colonize distal sites in the human body. Their enrichment in colorectal and breast cancer tissue has been associated with tumor growth, metastasis, and chemotherapeutic resistance. The use of non-selective antibiotics to remove fusobacteria impairs tumor progression, but prolonged application risks side effects such as gastrointestinal problems and dysbiosis. Species-specific antisense antibiotics based on peptide nucleic acid (PNA) have shown efficacy in many Gram-negative species, suggesting that antisense PNAs may also enable a tailored depletion of fusobacteria. Here, we have investigated the antibacterial potential of cell-penetrating peptide (CPP)-PNA conjugates targeting the mRNA of putative essential genes in Fusobacterium nucleatum . Unexpectedly, we observed no growth inhibition with any of the target-specific PNAs, but identified a non-targeting control CPP-PNA (FUS79, (RXR) 4 XB-GACATAATTGT) as a potent growth inhibitor of F. nucleatum . Our data suggest that the CPP and specific sequence features of FUS79 are responsible for its activity, rather than an antisense effect. Interestingly, FUS79 also inhibits the growth of five additional fusobacterial strains but not of F. nucleatum ssp. vincentii (FNV). RNA-seq analysis indicates that FUS79 induces a membrane stress response in a vulnerable F. nucleatum strain but not in FNV. Collectively, our attempt at developing antisense antibiotics for fusobacteria discovers a potent growth inhibitor, whose bactericidal effect appears independent of target-specific mRNA inhibition. IMPORTANCE: Enrichment of F. nucleatum at cancer sites is associated with increased tumor growth and metastasis. Antibiotic treatment to remove the bacteria was shown to change the course of cancer progression. Here we explore first steps to establish peptide nucleic acids (PNAs) as specific antisense antibiotics, thereby laying the foundation for further development of antisense technology in fusobacteria. While the CPP-PNA FUS79 was initially designed as a control, we observed that the compound was bactericidal for specific fusobacterial strains. Our results suggest that FUS79 might be able to selectively deplete fusobacterial strains from bacterial communities, offering a new perspective on fusobacterial removal at the tumor site.

  • Open Access

    ASOBIOTICS 2024: an interdisciplinary symposium on antisense-based programmable RNA antibiotics

    by Jörg Vogel, Franziska Faber, Lars Barquist, Anke Sparmann, Linda Popella, Chandradhish Ghosh

    The international symposium ASOBIOTICS 2024 brought together scientists across disciplines to discuss the challenges of advancing antibacterial antisense oligomers (ASOs) from basic research to clinical application. Hosted by the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, Germany, on September 12–13, 2024, the event featured presentations covering major milestones and current challenges of this antimicrobial technology and its applications against pathogens, commensals, and bacterial viruses. General design principles and modification of ASOs based on peptide nucleic acid (PNA) or phosphorodiamidate-morpholino-oligomer (PMO) chemistry, promising cellular RNA targets, new delivery technologies, as well as putative resistance mechanisms, were discussed. A panel discussion noted the challenge of nomenclature: antibacterial ASOs lack a single, universally used name. To address this, the term “asobiotics” was proposed to unite a community of like-minded scientists that are committed to advancing ASOs as antimicrobials. A consistent name will simplify literature searches and help scientists and funders appreciate the potential of programmable RNA antibiotics to combat antimicrobial resistance and enable precise microbiome editing.